


P.O.C.L. 10105

Attorney's Doc. No. VANM143.001APC

Page 1



# DECLARATION - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS; the specification of which was internationally filed on August 20, 1998, as International Application No. PCT/BE98/00124, and for which the initial documents for entry into the U.S. National Phase were filed on February 22, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## PRIOR FOREIGN APPLICATION(S)

Priority  
Claimed

No.: 9700692

Country: Belgium

Date Filed: August 20, 1997

Yes

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Bernard Knoops

Inventor's signature X [Signature]

Date 07-08-00


1-00

Residence: rue Chapelle Notre-Dame 3/1, B-1341 Cernoux-Mousty, BELGIUM *BEX*

Citizenship: Belgium

Post Office Address: Same as Above

2-00 Full name of Second inventor: Cedric Hermans

Inventor's signature *X* 

Date 07-08-00

Residence: avenue des Glycines 42, B-1030 Brussels, BELGIUM *BEX*

Citizenship: Belgium

Post Office Address: Same as Above

3-00 Full name of Third inventor: Alfred Bernard

Inventor's signature *X* 

Date 07-08-00

Residence: avenue de la Chapelle 6, B-1200 Brussels, BELGIUM *BEX*

Citizenship: Belgium

Post Office Address: Same as Above

4-00 Full name of Fourth inventor: Ruddy Wattiez

Inventor's signature *X* 

Date 07-08-00

Residence: chemin du Sauvelon 17, B-7022 Hyon, BELGIUM *BEX*

Citizenship: Belgium

Post Office Address: Same as Above



P. UCL. 58/US

Applicants: Knoops et al.  
Int'l. Application No.: PCT/BE98/00124  
Int'l. Filed: August 20, 1998

Attorney's Patent No.: VANM143.001APC  
Page 1

#3

For: **PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID  
POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES  
AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS**



**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL-ENTITY STATUS**

I, the undersigned, do hereby declare that:

☒ I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: UNIVERSITE CATHOLIQUE DE LOUVAIN

ADDRESS OF CONCERN: Halles Universitaires, Place de l'Université 1, B-1348 Louvain-La-Neuve,  
BELGIUM

I further declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. I further declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in the patent or application identified above.

The individual, concern or organization identified above has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

If the rights held by the above-identified individual, concern or organization are not exclusive, each individual, concern or organization having rights in the invention are identified below. Each such individual, concern or organization must file separate verified statements averring to their status as small entities.

**\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).**

FULL NAME: UNIVERSITE DE MONS-HAINAUT

ADDRESS: Place du Parc 20, B-7000 Mons, BELGIUM

☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small-entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Attorney's Ref No.: VANM143.001APC

Int'l. Application No.: PCT/BE98/00124

Page 2

Int'l. Filed: August 20, 1998

**For: PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS**

NAME OF PERSON SIGNING:

MARCO CROCHET

MARCEL CROCHET

TITLE OF PERSON (if not an owner or individual): *Rector*

Rector

ADDRESS OF PERSON SIGNING: Halles Universitaires, Place de l'Université 1, B-1348 Louvain-La-Neuve,  
BELGIUM

SIGNATURE:

DATE:

H:\DOCS\JAH\JAH-2147.DOC  
022800

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100